Securities Code: 300702
Securities Abbreviation: Tianyu Shares
Announcement Number: 2026-064
Zhejiang Tianyu Pharmaceutical Co., Ltd.
Announcement on Company's API Passing CDE Review
The board of directors and all directors guarantee that the content of this announcement is free from false records, misleading statements or major omissions, and they shall bear individual and joint responsibility for the authenticity, accuracy and completeness of their contents.
Zhejiang Tianyu Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") announced that its Brexpiprazole API has recently passed the review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration. The relevant situation is hereby announced as follows: